JCOG 9907 — A Randomized Controlled Trial of Chemotherapy With 5-FU and Cisplatin Before and After Surgery for Stage II/III Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)

Phase III · 2012 · Esophageal Cancer

Design

Randomized phase III trial comparing two courses of cisplatin plus 5-fluorouracil given postoperatively (surgery first) versus preoperatively (chemotherapy first) in resectable thoracic esophageal squamous cell carcinoma.

Population

Patients with clinical stage II or III (excluding T4) squamous cell carcinoma of the thoracic esophagus.

Primary Endpoint

Progression-free survival

Key Result

Preoperative chemotherapy was superior, with 5-year overall survival of 55% versus 43% for postoperative chemotherapy (hazard ratio 0.73; 95% CI, 0.54-0.99; P = .04).

Guideline Impact

Made preoperative CF chemotherapy the Japanese standard for resectable stage II/III esophageal SCC